Walnut Creek, Calif.-based Providence Medical Technology closed a new equity financing round of $10.5 million.
Here are five points:
1. The company plans to use the funding to boost the commercialization of its cervical fusion technology portfolio.
2. London, U.K.-based MVM Life Science Partners, a new investor, led the financing. The company is now a part of Providence's board of directors.
3. Jupiter, Fla.-based Stanmore Medical Investments and Mill Valley, Calif.-based Aphelion Capital also participated in the financing round.
4. Providence develops tissue-sparing, cervical fusion technology.
5. The company is currently working on commercializing the DTRAX platform of single-use, tissue-sparing instruments and CAVUX implants for cervical fusion.